Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Development of an Infection-Responsive Fluorescent Sensor for the Early Detection of Urinary Catheter Blockage.

Milo S, Acosta FB, Hathaway HJ, Wallace LA, Thet NT, Jenkins ATA.

ACS Sens. 2018 Mar 23;3(3):612-617. doi: 10.1021/acssensors.7b00861. Epub 2018 Feb 14.

PMID:
29443508
2.

Innate Sex Bias of Staphylococcus aureus Skin Infection Is Driven by α-Hemolysin.

Castleman MJ, Pokhrel S, Triplett KD, Kusewitt DF, Elmore BO, Joyner JA, Femling JK, Sharma G, Hathaway HJ, Prossnitz ER, Hall PR.

J Immunol. 2018 Jan 15;200(2):657-668. doi: 10.4049/jimmunol.1700810. Epub 2017 Dec 8.

PMID:
29222165
3.

The R-Enantiomer of Ketorolac Delays Mammary Tumor Development in Mouse Mammary Tumor Virus-Polyoma Middle T Antigen (MMTV-PyMT) Mice.

Peretti AS, Dominguez D, Grimes MM, Hathaway HJ, Prossnitz ER, Rivera MR, Wandinger-Ness A, Kusewitt DF, Hudson LG.

Am J Pathol. 2018 Feb;188(2):515-524. doi: 10.1016/j.ajpath.2017.10.018. Epub 2017 Nov 21.

PMID:
29169987
4.

Recent advances in therapeutic delivery systems of bacteriophage and bacteriophage-encoded endolysins.

Hathaway H, Milo S, Sutton JM, Jenkins TA.

Ther Deliv. 2017 Jul;8(7):543-556. doi: 10.4155/tde-2017-0040.

PMID:
28633592
5.

Thermally triggered release of the bacteriophage endolysin CHAPK and the bacteriocin lysostaphin for the control of methicillin resistant Staphylococcus aureus (MRSA).

Hathaway H, Ajuebor J, Stephens L, Coffey A, Potter U, Sutton JM, Jenkins AT.

J Control Release. 2017 Jan 10;245:108-115. doi: 10.1016/j.jconrel.2016.11.030. Epub 2016 Nov 28.

6.

Cold-inducible RNA binding protein in mouse mammary gland development.

Lujan DA, Garcia S, Vanderhoof J, Sifuentes J, Brandt Y, Wu Y, Guo X, Mitchell T, Howard T, Hathaway HJ, Hartley RS.

Tissue Cell. 2016 Dec;48(6):577-587. doi: 10.1016/j.tice.2016.10.004. Epub 2016 Nov 5.

PMID:
27837912
7.

Poly(N-isopropylacrylamide-co-allylamine) (PNIPAM-co-ALA) nanospheres for the thermally triggered release of Bacteriophage K.

Hathaway H, Alves DR, Bean J, Esteban PP, Ouadi K, Sutton JM, Jenkins AT.

Eur J Pharm Biopharm. 2015 Oct;96:437-41. doi: 10.1016/j.ejpb.2015.09.013. Epub 2015 Sep 28.

PMID:
26423908
8.

Study into the kinetic properties and surface attachment of a thermostable adenylate kinase.

Hathaway HJ, Sutton JM, Jenkins AT.

Biochem Biophys Rep. 2015 May;1:1-7.

9.

Atypical signaling of metabotropic glutamate receptor 1 in human melanoma cells.

Gelb T, Pshenichkin S, Hathaway HA, Grajkowska E, Dalley CB, Wolfe BB, Wroblewski JT.

Biochem Pharmacol. 2015 Nov 1;98(1):182-9. doi: 10.1016/j.bcp.2015.08.091. Epub 2015 Aug 17.

PMID:
26291396
10.

What have we learned about GPER function in physiology and disease from knockout mice?

Prossnitz ER, Hathaway HJ.

J Steroid Biochem Mol Biol. 2015 Sep;153:114-26. doi: 10.1016/j.jsbmb.2015.06.014. Epub 2015 Jul 16. Review.

11.

Magnetic relaxometry as applied to sensitive cancer detection and localization.

De Haro LP, Karaulanov T, Vreeland EC, Anderson B, Hathaway HJ, Huber DL, Matlashov AN, Nettles CP, Price AD, Monson TC, Flynn ER.

Biomed Tech (Berl). 2015 Oct;60(5):445-55. doi: 10.1515/bmt-2015-0053.

12.

Pharmacological characterization of mGlu1 receptors in cerebellar granule cells reveals biased agonism.

Hathaway HA, Pshenichkin S, Grajkowska E, Gelb T, Emery AC, Wolfe BB, Wroblewski JT.

Neuropharmacology. 2015 Jun;93:199-208. doi: 10.1016/j.neuropharm.2015.02.007. Epub 2015 Feb 17.

13.

Triple threat treatment: Exploiting the dependence receptor properties of metabotropic glutamate receptor 1 against melanoma.

Gelb T, Hathaway HA, Wroblewski JT.

Mol Cell Oncol. 2014 Nov 11;1(4):e969163. doi: 10.4161/23723548.2014.969163. eCollection 2014 Oct-Dec.

14.

Metabotropic glutamate receptor 1 acts as a dependence receptor creating a requirement for glutamate to sustain the viability and growth of human melanomas.

Gelb T, Pshenichkin S, Rodriguez OC, Hathaway HA, Grajkowska E, DiRaddo JO, Wroblewska B, Yasuda RP, Albanese C, Wolfe BB, Wroblewski JT.

Oncogene. 2015 May 21;34(21):2711-20. doi: 10.1038/onc.2014.231. Epub 2014 Jul 28.

15.

GPER-targeted, 99mTc-labeled, nonsteroidal ligands demonstrate selective tumor imaging and in vivo estrogen binding.

Nayak TK, Ramesh C, Hathaway HJ, Norenberg JP, Arterburn JB, Prossnitz ER.

Mol Cancer Res. 2014 Nov;12(11):1635-43. doi: 10.1158/1541-7786.MCR-14-0289. Epub 2014 Jul 16.

16.

G protein-coupled estrogen receptor regulates mammary tumorigenesis and metastasis.

Marjon NA, Hu C, Hathaway HJ, Prossnitz ER.

Mol Cancer Res. 2014 Nov;12(11):1644-1654. doi: 10.1158/1541-7786.MCR-14-0128-T. Epub 2014 Jul 16.

17.

GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast.

Scaling AL, Prossnitz ER, Hathaway HJ.

Horm Cancer. 2014 Jun;5(3):146-160. doi: 10.1007/s12672-014-0174-1. Epub 2014 Apr 10.

18.

A real-time method for measuring cAMP production modulated by Gαi/o-coupled metabotropic glutamate receptors.

DiRaddo JO, Miller EJ, Hathaway HA, Grajkowska E, Wroblewska B, Wolfe BB, Liotta DC, Wroblewski JT.

J Pharmacol Exp Ther. 2014 Jun;349(3):373-82. doi: 10.1124/jpet.113.211532. Epub 2014 Mar 21.

19.

Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides.

Lu J, Hathaway HJ, Royce ME, Prossnitz ER, Miao Y.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):725-30. doi: 10.1016/j.bmcl.2013.12.120. Epub 2014 Jan 6.

20.

G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth.

Petrie WK, Dennis MK, Hu C, Dai D, Arterburn JB, Smith HO, Hathaway HJ, Prossnitz ER.

Obstet Gynecol Int. 2013;2013:472720. doi: 10.1155/2013/472720. Epub 2013 Nov 27.

21.

Influences of hydrocarbon linkers on the receptor binding affinities of gonadotropin-releasing hormone peptides.

Guo H, Hathaway H, Royce ME, Prossnitz ER, Miao Y.

Bioorg Med Chem Lett. 2013 Oct 15;23(20):5484-7. doi: 10.1016/j.bmcl.2013.08.075. Epub 2013 Aug 23.

22.

GPER deficiency in male mice results in insulin resistance, dyslipidemia, and a proinflammatory state.

Sharma G, Hu C, Brigman JL, Zhu G, Hathaway HJ, Prossnitz ER.

Endocrinology. 2013 Nov;154(11):4136-45. doi: 10.1210/en.2013-1357. Epub 2013 Aug 22.

23.

Targeting the transposase domain of the DNA repair component Metnase to enhance chemotherapy.

Williamson EA, Damiani L, Leitao A, Hu C, Hathaway H, Oprea T, Sklar L, Shaheen M, Bauman J, Wang W, Nickoloff JA, Lee SH, Hromas R.

Cancer Res. 2012 Dec 1;72(23):6200-8. doi: 10.1158/0008-5472.CAN-12-0313. Epub 2012 Oct 22.

24.

Development of antibody-tagged nanoparticles for detection of transplant rejection using biomagnetic sensors.

Butler KS, Lovato DM, Adolphi NL, Belfon R, Fegan DL, Monson TC, Hathaway HJ, Huber DL, Tessier TE, Bryant HC, Flynn ER, Larson RS.

Cell Transplant. 2013;22(10):1943-54. doi: 10.3727/096368912X657963. Epub 2012 Oct 12.

PMID:
23069078
25.

Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein.

Béraud D, Hathaway HA, Trecki J, Chasovskikh S, Johnson DA, Johnson JA, Federoff HJ, Shimoji M, Mhyre TR, Maguire-Zeiss KA.

J Neuroimmune Pharmacol. 2013 Mar;8(1):94-117. doi: 10.1007/s11481-012-9401-0. Epub 2012 Oct 10.

26.

Ligand bias at metabotropic glutamate 1a receptors: molecular determinants that distinguish β-arrestin-mediated from G protein-mediated signaling.

Emery AC, DiRaddo JO, Miller E, Hathaway HA, Pshenichkin S, Takoudjou GR, Grajkowska E, Yasuda RP, Wolfe BB, Wroblewski JT.

Mol Pharmacol. 2012 Aug;82(2):291-301. doi: 10.1124/mol.112.078444. Epub 2012 May 14.

27.

Imaging of Her2-targeted magnetic nanoparticles for breast cancer detection: comparison of SQUID-detected magnetic relaxometry and MRI.

Adolphi NL, Butler KS, Lovato DM, Tessier TE, Trujillo JE, Hathaway HJ, Fegan DL, Monson TC, Stevens TE, Huber DL, Ramu J, Milne ML, Altobelli SA, Bryant HC, Larson RS, Flynn ER.

Contrast Media Mol Imaging. 2012 May-Jun;7(3):308-19. doi: 10.1002/cmmi.499.

28.

Microenvironmental control of the breast cancer cell cycle.

Guo X, Wu Y, Hathaway HJ, Hartley RS.

Anat Rec (Hoboken). 2012 Apr;295(4):553-62. doi: 10.1002/ar.22417. Epub 2012 Jan 24. Review.

29.

Deletion of G protein-coupled estrogen receptor increases endothelial vasoconstriction.

Meyer MR, Amann K, Field AS, Hu C, Hathaway HJ, Kanagy NL, Walker MK, Barton M, Prossnitz ER.

Hypertension. 2012 Feb;59(2):507-12. doi: 10.1161/HYPERTENSIONAHA.111.184606. Epub 2011 Dec 27.

30.

Detection of breast cancer cells using targeted magnetic nanoparticles and ultra-sensitive magnetic field sensors.

Hathaway HJ, Butler KS, Adolphi NL, Lovato DM, Belfon R, Fegan D, Monson TC, Trujillo JE, Tessier TE, Bryant HC, Huber DL, Larson RS, Flynn ER.

Breast Cancer Res. 2011 Nov 3;13(5):R108. doi: 10.1186/bcr3050.

31.

Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity.

Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologa CG, Oprea TI, Yamaguchi Y, Hayashi S, Sklar LA, Hathaway HJ, Arterburn JB, Prossnitz ER.

J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):358-66. doi: 10.1016/j.jsbmb.2011.07.002. Epub 2011 Jul 14.

32.

Synthesis and evaluation of novel gonadotropin-releasing hormone receptor-targeting peptides.

Guo H, Lu J, Hathaway H, Royce ME, Prossnitz ER, Miao Y.

Bioconjug Chem. 2011 Aug 17;22(8):1682-9. doi: 10.1021/bc200252j. Epub 2011 Jul 20.

33.

Characterization of single-core magnetite nanoparticles for magnetic imaging by SQUID relaxometry.

Adolphi NL, Huber DL, Bryant HC, Monson TC, Fegan DL, Lim J, Trujillo JE, Tessier TE, Lovato DM, Butler KS, Provencio PP, Hathaway HJ, Majetich SA, Larson RS, Flynn ER.

Phys Med Biol. 2010 Oct 7;55(19):5985-6003. doi: 10.1088/0031-9155/55/19/023. Epub 2010 Sep 21.

34.

Three-dimensional collagen represses cyclin E1 via β1 integrin in invasive breast cancer cells.

Wu Y, Guo X, Brandt Y, Hathaway HJ, Hartley RS.

Breast Cancer Res Treat. 2011 Jun;127(2):397-406. doi: 10.1007/s10549-010-1013-x. Epub 2010 Jul 4.

35.

Influence of charge on cell permeability and tumor imaging of GPR30-targeted 111in-labeled nonsteroidal imaging agents.

Nayak TK, Dennis MK, Ramesh C, Burai R, Atcher RW, Sklar LA, Norenberg JP, Hathaway HJ, Arterburn JB, Prossnitz ER.

ACS Chem Biol. 2010 Jul 16;5(7):681-90. doi: 10.1021/cb1000636.

36.

Characterization of magnetite nanoparticles for SQUID-relaxometry and magnetic needle biopsy.

Adolphi NL, Huber DL, Jaetao JE, Bryant HC, Lovato DM, Fegan DL, Venturini EL, Monson TC, Tessier TE, Hathaway HJ, Bergemann C, Larson RS, Flynn ER.

J Magn Magn Mater. 2009 May 1;321(10):1459-1464.

37.

Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30.

Ramesh C, Nayak TK, Burai R, Dennis MK, Hathaway HJ, Sklar LA, Prossnitz ER, Arterburn JB.

J Med Chem. 2010 Feb 11;53(3):1004-14. doi: 10.1021/jm9011802.

38.

Enhanced leukemia cell detection using a novel magnetic needle and nanoparticles.

Jaetao JE, Butler KS, Adolphi NL, Lovato DM, Bryant HC, Rabinowitz I, Winter SS, Tessier TE, Hathaway HJ, Bergemann C, Flynn ER, Larson RS.

Cancer Res. 2009 Nov 1;69(21):8310-6. doi: 10.1158/0008-5472.CAN-09-1083. Epub 2009 Oct 6.

39.

GPR30 predicts poor survival for ovarian cancer.

Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER.

Gynecol Oncol. 2009 Sep;114(3):465-71. doi: 10.1016/j.ygyno.2009.05.015. Epub 2009 Jun 6.

40.

In vivo effects of a GPR30 antagonist.

Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK, Bologa CG, Leitao A, Brailoiu E, Deliu E, Dun NJ, Sklar LA, Hathaway HJ, Arterburn JB, Oprea TI, Prossnitz ER.

Nat Chem Biol. 2009 Jun;5(6):421-7. doi: 10.1038/nchembio.168.

41.

Preclinical development of a neutral, estrogen receptor-targeted, tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers.

Nayak TK, Hathaway HJ, Ramesh C, Arterburn JB, Dai D, Sklar LA, Norenberg JP, Prossnitz ER.

J Nucl Med. 2008 Jun;49(6):978-86. doi: 10.2967/jnumed.107.048546. Epub 2008 May 15.

42.

Anti-Xa stability of diluted dalteparin for pediatric use.

Goldenberg NA, Jacobson L, Hathaway H, Tripputi M, Primeaux J, Child J.

Ann Pharmacother. 2008 Apr;42(4):511-5. doi: 10.1345/aph.1K609. Epub 2008 Mar 18.

PMID:
18349310
43.

Estrogen signaling through the transmembrane G protein-coupled receptor GPR30.

Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ.

Annu Rev Physiol. 2008;70:165-90. doi: 10.1146/annurev.physiol.70.113006.100518. Review.

PMID:
18271749
44.
45.

Apoptosis and involution in the mammary gland are altered in mice lacking a novel receptor, beta1,4-Galactosyltransferase I.

de la Cruz L, Steffgen K, Martin A, McGee C, Hathaway H.

Dev Biol. 2004 Aug 15;272(2):286-309.

46.
47.

Mutational analysis of the cytoplasmic domain of beta1,4-galactosyltransferase I: influence of phosphorylation on cell surface expression.

Hathaway HJ, Evans SC, Dubois DH, Foote CI, Elder BH, Shur BD.

J Cell Sci. 2003 Nov 1;116(Pt 21):4319-30. Epub 2003 Sep 9.

48.
50.

Supplemental Content

Loading ...
Support Center